{"protocolSection": {"identificationModule": {"nctId": "NCT02937454", "orgStudyIdInfo": {"id": "FER-CARS-06"}, "secondaryIdInfos": [{"id": "2016-001467-36", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Vifor Pharma", "class": "INDUSTRY"}, "briefTitle": "Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency", "officialTitle": "A Randomised, Double-Blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure (Affirm-AHF)", "acronym": "Affirm-AHF"}, "statusModule": {"statusVerifiedDate": "2021-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-04-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-07-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-07-21", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-10-14", "studyFirstSubmitQcDate": "2016-10-14", "studyFirstPostDateStruct": {"date": "2016-10-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-04-23", "resultsFirstSubmitQcDate": "2021-05-25", "resultsFirstPostDateStruct": {"date": "2021-06-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-05-25", "lastUpdatePostDateStruct": {"date": "2021-06-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Vifor (International) Inc.", "class": "INDUSTRY"}, "collaborators": [{"name": "Worldwide Clinical Trials", "class": "OTHER"}, {"name": "Cytel Inc.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency (Affirm-AHF)", "detailedDescription": "This is a randomised, double-blind, placebo-controlled Trial (RCT). The 52 weeks observation period following randomisation is considered appropriate to investigate the primary endpoint of recurrent HF hospitalisations and CV death. To evaluate the effect of intravenous ferric carboxymaltose (IV FCM) in iron deficient subjects with AHF, subjects will be enrolled during a hospital stay (Index hospitalisation) after the acute care treatment of the index event has been stabilised. All subjects will continue to receive their established standard therapy for HF and medical emergencies will be treated according to local routine."}, "conditionsModule": {"conditions": ["Iron Deficiency", "Heart Failure"], "keywords": ["Acute Heart Failure", "Iron Deficiency"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 1132, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "ferric carboxymaltose", "type": "ACTIVE_COMPARATOR", "description": "The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.", "interventionNames": ["Drug: ferric carboxymaltose"]}, {"label": "normal saline 0.9%", "type": "PLACEBO_COMPARATOR", "description": "The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.", "interventionNames": ["Other: Normal saline 0.9%"]}], "interventions": [{"type": "DRUG", "name": "ferric carboxymaltose", "description": "FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered", "armGroupLabels": ["ferric carboxymaltose"], "otherNames": ["Injectafer", "Ferinject", "Renegy", "Iroprem"]}, {"type": "OTHER", "name": "Normal saline 0.9%", "description": "Normal saline will be administered as a bolus injection.", "armGroupLabels": ["normal saline 0.9%"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "HF Hospitalizations and CV Death", "description": "HF = Heart Failure, CV = Cardiovascular.\n\nThe composite of recurrent HF hospitalizations and CV death up to 52 weeks after randomization\n\nTotal hospitalisations included first and recurrent events. If a participant was hospitalised for heart failure and died within 24 h from any cardiovascular event, this was counted as one event.", "timeFrame": "up to 52 weeks after randomization"}], "secondaryOutcomes": [{"measure": "Recurrent CV Hospitalisations and CV Death", "description": "CV = Cardiovascular\n\nThe composite of recurrent CV hospitalisations and CV death at 52 weeks after randomisation\n\nTotal hospitalisations included first and recurrent events. If a participant was hospitalised for a cardiovascular reason and died within 24 h of admission from any cardiovascular event, this was counted as one event.", "timeFrame": "up to 52 weeks after randomization"}, {"measure": "HF Hospitalisations", "description": "HF = Heart Failure\n\nHF hospitalisations up to 52 weeks after randomisation analysed as recurrent event.", "timeFrame": "up to 52 weeks after randomisation"}, {"measure": "CV Mortality", "description": "CV = Cardiovascular\n\nCV mortality analysed as time to first event at 52 weeks after randomisation.", "timeFrame": "at 52 weeks after randomisation."}, {"measure": "Composite of HF Hospitalisations or CV Death", "description": "HF = Heart Failure, CV = Cardiovascular\n\nAnalysed as time to first event at 52 weeks after randomisation. The number of participants with at least one HF Hospitalisation or CV Death is presented below.", "timeFrame": "at 52 weeks after randomisation"}, {"measure": "Days Lost Due to HF Hospitalisation or CV Death", "description": "HF = Heart Failure, CV = Cardiovascular\n\nNumber of days lost due to heart failure hospitalisations or cardiovascular death corresponds to the total number of days in hospital for heart failure from randomisation to last known date. Days lost due to cardiovascular death are added to the number of days lost due to heart failure hospitalisation.", "timeFrame": "at 52 weeks after randomisation"}], "otherOutcomes": [{"measure": "HF Hospitalisations", "description": "HF = Heart Failure\n\nNumber of participants with at least one HF Hospitalisation up to 52 weeks after randomisation", "timeFrame": "up to 52 weeks after randomisation"}, {"measure": "CV Hospitalisations", "description": "CV = Cardiovascular\n\nNumber of participants with at least one CV Hospitalisation up to 52 weeks after randomisation", "timeFrame": "up to 52 weeks after randomisation"}, {"measure": "All-cause Mortality", "description": "Number of participants who died up to 52 weeks after randomisation", "timeFrame": "up to 52 weeks after randomisation"}, {"measure": "Change From Baseline in NYHA Functional Class", "description": "NYHA = New York Heart Association\n\nNYHA functional class was assessed as Class I, II, III, IV or V:\n\nClass I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.\n\nClass II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.\n\nClass III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest.\n\nClass IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. If a participant was hospitalised at any point during any post-baseline visit and did not have any NYHA assessment for this visit, then Class IV was to be imputed for the visit.\n\nClass V - Imputed for participants who died.\n\nLower response categories are better for score NYHA.", "timeFrame": "at 6, 12, 24 and 52 weeks after randomisation"}, {"measure": "Change From Baseline in the EQ-5D-5L Questionnaire Indexed Value", "description": "EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels\n\nThe EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration.\n\nThe descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).", "timeFrame": "at 6, 24 and 52 weeks after randomisation"}, {"measure": "KCCQ-12 Repeated-Measures Model for Analysis of Treatment Difference", "description": "KCCQ = Kansas City Cardiomyopathy Questionnaire\n\nThe KCCQ 12 is a health-related quality of life questionnaire for Heart Failure. It is a 12 item questionnaire that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge and Quality of life. Scores are generated for each domain and scaled from 0 to 100, with 0 denoting the lowest reportable health status and 100 the highest reportable health status.", "timeFrame": "up to 52 weeks after randomisation"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Currently hospitalised for an episode of acute heart failure (AHF) where AHF was the primary reason for hospitalisation. All of the following (i.e., items a to d) must apply:\n\n   1. Upon admission for the AHF episode, persistent dyspnoea at rest in a recumbent sitting position (30-45\u00b0) or with minimal exertion\n   2. Upon or during the AHF admission, at least 2 of the following clinical findings were present: i. Congestion on chest X-ray ii. Rales on chest auscultation iii. Oedema \u22651+ on a 0-3+ scale, indicating indentation of skin with mild digital pressure that requires 10 or more seconds to resolve in any dependent area including extremities or sacral region iv. Elevated jugular venous pressure (\u22658 cm H2O)\n   3. Natriuretic peptide levels, measured \u226472 hours of the AHF admission must have been: i. Brain natriuretic peptide (BNP) \u2265400 pg/mL or N-terminal-pro-brain natriuretic peptide (NT-proBNP) \u22651,600 pg/mL or ii. BNP \u2265600 pg/mL or NT-proBNP \u22652,400 pg/mL for subjects presenting with atrial fibrillation when the blood sample was taken iii. For subjects treated with an angiotensin receptor neprilysin inhibitor (ARNI) in the previous 4 weeks prior to randomisation only NT-proBNP values should be considered\n   4. AHF episode treated with minimally 40 mg of IV furosemide (or equivalent IV loop diuretic defined as 20 mg of torasemide or 1 mg of bumetanide)\n2. Subject is iron deficient defined as serum ferritin \\<100 ng/mL or 100 ng/mL \u2264 serum ferritin \u2264299 ng/mL if TSAT \\<20%.\n3. Left ventricular ejection fraction \\<50% (assessed and documented within 12 months prior to randomisation).\n4. Male or female aged \u226518 years old.\n5. Subject (or legally acceptable representative)\\* has provided the appropriate written informed consent. Subject must provide written informed consent before any study-specific procedures are performed.\n\nExclusion Criteria:\n\n1. Dyspnoea due to non-cardiac causes such as acute or chronic respiratory disorders or infections (i.e., severe chronic obstructive pulmonary disease, acute bronchitis, pneumonia, primary pulmonary hypertension).\n2. Temperature \\>38\u00b0C (oral or equivalent), active infective endocarditis, sepsis, systemic inflammatory response syndrome, or any other active infection requiring anti-microbial treatment at any time during an Index hospitalisation. (Note that it does NOT include short-term prophylactic administration of antibiotics or short-term temperature elevation at admission which is no longer present at the time point of discharge/randomisation).\n3. Documented restricted amyloid myocardiopathy, or acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy. (Note that it does NOT include restrictive mitral filling patterns seen on Doppler echocardiographic assessments of diastolic function).\n4. Clinical evidence of acute coronary syndrome, transient ischemic attack or stroke, within the last 30 days prior randomisation.\n5. Severe valvular or left ventricular outflow obstruction disease needing intervention.\n6. Coronary-artery bypass graft, cardiac resynchronisation therapy device implantation, percutaneous intervention (e.g., cardiac, cerebrovascular, aortic, diagnostic catheters are allowed) or major surgery that led to significant blood loss, including thoracic and cardiac surgery, within the last 3 months prior to randomisation.\n7. Subject has a body weight \\<35 kg at randomisation.\n8. Subject at an immediate need of transfusion or with a Hb \\<8 g/dL\\* or with a Hb \\>15 g/dL.\n9. Subjects on treatment for Vitamin B12 and/or serum folate deficiency. Note: Use of Vitamin B12 and folic acid as supplement therapy (not for deficiency treatment) is permitted.\n10. Subject with a known anaemia not attributed to ID (e.g., other microcytic anaemia) or with an evidence of iron overload (e.g., haemochromatosis) or disturbances in the utilisation of iron.\n11. Subject has known hypersensitivity to any of the study products to be administered or known serious hypersensitivity to other parenteral iron products.\n12. Subject with known severe allergies including drug allergies, history of severe asthma, eczema or other atopic allergy and in subjects with immune or inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis).\n13. History of erythropoietin stimulating agent, IV iron therapy, and/or blood transfusion in previous 3 months prior to randomisation.\n14. Oral iron therapy at doses \\>100 mg/day in previous 4 weeks prior to randomisation. Note: Ongoing use of multivitamins containing iron \\<75 mg/day are permitted.\n15. Currently receiving systemic chemotherapy and/or radiotherapy.\n16. Renal dialysis (previous, current or planned within the next 6 months).\n17. Subject has known active malignancy of any organ system, i.e., clinical evidence of current malignancy or not in stable remission for at least 3 years since completion of last treatment with exception of non-invasive basal cell carcinoma, squamous cell carcinoma of the skin or cervical intra-epithelial neoplasia.\n18. Terminal illness other than HF with expected survival \\<12 months.\n19. Chronic liver disease (including active hepatitis) and/or alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range.\n20. Subjects with known hepatitis B surface antigen positivity and/or hepatitis C virus ribonucleic acid positivity.\n21. Subject previously randomised into this study. Note: Subjects may be rescreened but when rescreened, all tests must fall inside the maximum specified screening windows for each criterion.\n22. Subject is currently enrolled in or has completed any other investigational device or drug study \\<30 days prior to screening, or is receiving other investigational agent(s).\n23. Subject is pregnant (e.g., positive human chorionic gonadotropin test) or breast feeding.\n24. If of childbearing potential, subject is not using adequate contraceptive precautions. Subject must agree to use adequate contraception during the study and for 1 month after the last dose of study treatment. A highly effective method of birth control must be used.\n25. Subject has a history of drug or alcohol abuse within 2 years prior to screening.\n26. Subject has a significant medical condition(s), anticipated need for major surgery during the study, or any other kind of disorder that may be associated with increased risk to the subject, or may interfere with study assessments, outcomes, or the ability to provide written informed consent or comply with study procedures, in the Investigator's opinion.\n\n    * Following section in italics is applicable for The Netherlands, Spain and Singapore only (NL, ES and SG only): 'The lower threshold of Hb values is set to 10 g/dL.'", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Piotr Ponikowski, MD", "affiliation": "Medical University Clinical Military Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hospital Universitario Austral", "city": "Buenos Aires", "zip": "1500", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "InCor -Instituto do Cora\u00e7\u00e3o HCFMUSP", "city": "S\u00e3o Paulo", "zip": "05403-900", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Clinical Hospital Center Rijeka", "city": "Rijeka", "country": "Croatia", "geoPoint": {"lat": 45.32674, "lon": 14.44239}}, {"facility": "Aleksandre Aladashvili Clinic LLC", "city": "Tbilisi", "zip": "0102", "country": "Georgia", "geoPoint": {"lat": 41.69411, "lon": 44.83368}}, {"facility": "The Baruch Pade Medical Center", "city": "Tiberias", "state": "Lower Galilee", "zip": "15208", "country": "Israel", "geoPoint": {"lat": 32.79221, "lon": 35.53124}}, {"facility": "Hadassah Ein Kerem University Medical Center", "city": "Jerusalem", "zip": "91120", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Spedali Civilia di Brescia", "city": "Brescia", "country": "Italy", "geoPoint": {"lat": 45.53558, "lon": 10.21472}}, {"facility": "American University of Beirut Medical Center", "city": "Beirut", "zip": "1107-2020", "country": "Lebanon", "geoPoint": {"lat": 33.88894, "lon": 35.49442}}, {"facility": "Vasculair Onderzoek Centrum", "city": "Hoorn", "country": "Netherlands", "geoPoint": {"lat": 52.6425, "lon": 5.05978}}, {"facility": "Clinical Military Hospital", "city": "Wroclaw", "zip": "50-891", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Emergency Clinical Hospital", "city": "Bucharest", "zip": "014461", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "National Heart Centre of Singapore Pte", "city": "Singapore", "zip": "169609", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "University of Murcia", "city": "Murcia", "zip": "30001", "country": "Spain", "geoPoint": {"lat": 37.98704, "lon": -1.13004}}, {"facility": "Skane University Hospital", "city": "Malm\u00f6", "zip": "SE 20502", "country": "Sweden", "geoPoint": {"lat": 55.60587, "lon": 13.00073}}, {"facility": "The M.D. Strazhesko Institute of Cardiology", "city": "Kyiv", "zip": "02000", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Kings College Hospital NHS Foundation", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}]}, "referencesModule": {"references": [{"pmid": "33197395", "type": "DERIVED", "citation": "Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Gohring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA; AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020 Dec 12;396(10266):1895-1904. doi: 10.1016/S0140-6736(20)32339-4. Epub 2020 Nov 13. Erratum In: Lancet. 2021 Nov 27;398(10315):1964."}, {"pmid": "31883356", "type": "DERIVED", "citation": "Ponikowski P, Kirwan BA, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Khintibidze I, Kragten H, Martinez FA, McDonagh T, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Jankowska EA. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. Eur J Heart Fail. 2019 Dec;21(12):1651-1658. doi: 10.1002/ejhf.1710. Epub 2019 Dec 28."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "FG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "All Randomised Set", "achievements": [{"groupId": "FG000", "numSubjects": "567"}, {"groupId": "FG001", "numSubjects": "565"}]}, {"type": "Started Treatment", "achievements": [{"groupId": "FG000", "numSubjects": "559"}, {"groupId": "FG001", "numSubjects": "551"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "427"}, {"groupId": "FG001", "numSubjects": "437"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "140"}, {"groupId": "FG001", "numSubjects": "128"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "98"}, {"groupId": "FG001", "numSubjects": "95"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "5"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "BG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "559"}, {"groupId": "BG001", "value": "551"}, {"groupId": "BG002", "value": "1110"}]}], "measures": [{"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "<18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Between 18 and 64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "139"}, {"groupId": "BG001", "value": "142"}, {"groupId": "BG002", "value": "281"}]}]}, {"title": "Between 65 and 84 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "369"}, {"groupId": "BG001", "value": "370"}, {"groupId": "BG002", "value": "739"}]}]}, {"title": "\u2265 85 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "90"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "244"}, {"groupId": "BG001", "value": "250"}, {"groupId": "BG002", "value": "494"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "315"}, {"groupId": "BG001", "value": "301"}, {"groupId": "BG002", "value": "616"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "101"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "498"}, {"groupId": "BG001", "value": "489"}, {"groupId": "BG002", "value": "987"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "22"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Argentina", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "48"}]}]}, {"title": "Brazil", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "28"}]}]}, {"title": "Croatia", "categories": [{"measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "82"}]}]}, {"title": "Georgia", "categories": [{"measurements": [{"groupId": "BG000", "value": "98"}, {"groupId": "BG001", "value": "95"}, {"groupId": "BG002", "value": "193"}]}]}, {"title": "Israel", "categories": [{"measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "79"}]}]}, {"title": "Italy", "categories": [{"measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "113"}]}]}, {"title": "Lebanon", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "32"}]}]}, {"title": "Netherlands", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "69"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "90"}, {"groupId": "BG002", "value": "180"}]}]}, {"title": "Romania", "categories": [{"measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "154"}]}]}, {"title": "Singapore", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "45"}]}]}, {"title": "Spain", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "24"}]}]}, {"title": "Sweden", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "5"}]}]}, {"title": "Ukraine", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "46"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "HF Hospitalizations and CV Death", "description": "HF = Heart Failure, CV = Cardiovascular.\n\nThe composite of recurrent HF hospitalizations and CV death up to 52 weeks after randomization\n\nTotal hospitalisations included first and recurrent events. If a participant was hospitalised for heart failure and died within 24 h from any cardiovascular event, this was counted as one event.", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.\n\nThe management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events", "timeFrame": "up to 52 weeks after randomization", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"title": "Full Analysis Set (FAS)", "categories": [{"measurements": [{"groupId": "OG000", "value": "293"}, {"groupId": "OG001", "value": "372"}]}]}, {"title": "Covid-19 Sensitivity Analysis", "categories": [{"measurements": [{"groupId": "OG000", "value": "274"}, {"groupId": "OG001", "value": "363"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Full Analysis Set (FAS)", "nonInferiorityType": "OTHER", "pValue": "0.059", "statisticalMethod": "Negative binomial model", "statisticalComment": "Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.", "paramType": "Annualised event rate ratio (RR)", "paramValue": "0.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.62", "ciUpperLimit": "1.01"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Covid-19 Sensitivity Analysis", "nonInferiorityType": "OTHER", "pValue": "0.024", "statisticalMethod": "Negative binomial model", "statisticalComment": "Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.", "paramType": "Annualised event rate ratio (RR)", "paramValue": "0.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.59", "ciUpperLimit": "0.96"}]}, {"type": "SECONDARY", "title": "Recurrent CV Hospitalisations and CV Death", "description": "CV = Cardiovascular\n\nThe composite of recurrent CV hospitalisations and CV death at 52 weeks after randomisation\n\nTotal hospitalisations included first and recurrent events. If a participant was hospitalised for a cardiovascular reason and died within 24 h of admission from any cardiovascular event, this was counted as one event.", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.\n\nThe management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events", "timeFrame": "up to 52 weeks after randomization", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"title": "Full Analysis Set (FAS)", "categories": [{"measurements": [{"groupId": "OG000", "value": "370"}, {"groupId": "OG001", "value": "451"}]}]}, {"title": "COVID-19 sensitivity analyses", "categories": [{"measurements": [{"groupId": "OG000", "value": "350"}, {"groupId": "OG001", "value": "440"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Full Analysis Set (FAS)", "nonInferiorityType": "OTHER", "pValue": "0.050", "statisticalMethod": "Negative binomial model", "statisticalComment": "Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.", "paramType": "Annualised event rate ratio (RR)", "paramValue": "0.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.64", "ciUpperLimit": "1.0"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "COVID-19 sensitivity analyses", "nonInferiorityType": "OTHER", "pValue": "0.024", "statisticalMethod": "Negative binomial model", "statisticalComment": "Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.", "paramType": "Annualised event rate ratio (RR)", "paramValue": "0.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.62", "ciUpperLimit": "0.97"}]}, {"type": "SECONDARY", "title": "HF Hospitalisations", "description": "HF = Heart Failure\n\nHF hospitalisations up to 52 weeks after randomisation analysed as recurrent event.", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.\n\nThe management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events", "timeFrame": "up to 52 weeks after randomisation", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"title": "Full Analysis Set (FAS)", "categories": [{"measurements": [{"groupId": "OG000", "value": "217"}, {"groupId": "OG001", "value": "294"}]}]}, {"title": "COVID-19 sensitivity analyses", "categories": [{"measurements": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "287"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Full Analysis Set (FAS)", "nonInferiorityType": "OTHER", "pValue": "0.013", "statisticalMethod": "Negative binomial model", "statisticalComment": "Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.", "paramType": "Annualised event rate ratio (RR)", "paramValue": "0.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.58", "ciUpperLimit": "0.94"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "COVID-19 sensitivity analyses", "nonInferiorityType": "OTHER", "pValue": "0.005", "statisticalMethod": "Negative binomial model", "statisticalComment": "Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.", "paramType": "Annualised event rate ratio (RR)", "paramValue": "0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.55", "ciUpperLimit": "0.90"}]}, {"type": "SECONDARY", "title": "CV Mortality", "description": "CV = Cardiovascular\n\nCV mortality analysed as time to first event at 52 weeks after randomisation.", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.\n\nThe management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "at 52 weeks after randomisation.", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"title": "Full Analysis Set (FAS)", "categories": [{"measurements": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "78"}]}]}, {"title": "COVID-19 sensitivity analyses", "categories": [{"measurements": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "76"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Full Analysis Set (FAS)", "nonInferiorityType": "OTHER", "pValue": "0.809", "statisticalMethod": "Regression, Cox", "statisticalComment": "Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline.", "paramType": "Hazard Ratio (HR)", "paramValue": "0.96", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.70", "ciUpperLimit": "1.32"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Covid-19 Sensitivity Analysis", "nonInferiorityType": "OTHER", "pValue": "0.687", "statisticalMethod": "Regression, Cox", "statisticalComment": "Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline", "paramType": "Hazard Ratio (HR)", "paramValue": "0.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.68", "ciUpperLimit": "1.29"}]}, {"type": "SECONDARY", "title": "Composite of HF Hospitalisations or CV Death", "description": "HF = Heart Failure, CV = Cardiovascular\n\nAnalysed as time to first event at 52 weeks after randomisation. The number of participants with at least one HF Hospitalisation or CV Death is presented below.", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.\n\nThe management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "at 52 weeks after randomisation", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"title": "Full Analysis Set (FAS)", "categories": [{"measurements": [{"groupId": "OG000", "value": "181"}, {"groupId": "OG001", "value": "209"}]}]}, {"title": "COVID-19 sensitivity analyses", "categories": [{"measurements": [{"groupId": "OG000", "value": "175"}, {"groupId": "OG001", "value": "205"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Full Analysis Set (FAS)", "nonInferiorityType": "OTHER", "pValue": "0.030", "statisticalMethod": "Regression, Cox", "statisticalComment": "Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline", "paramType": "Hazard Ratio (HR)", "paramValue": "0.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.66", "ciUpperLimit": "0.98"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Covid-19 Sensitivity Analysis", "nonInferiorityType": "OTHER", "pValue": "0.023", "statisticalMethod": "Regression, Cox", "statisticalComment": "Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline", "paramType": "Hazard Ratio (HR)", "paramValue": "0.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.65", "ciUpperLimit": "0.97"}]}, {"type": "SECONDARY", "title": "Days Lost Due to HF Hospitalisation or CV Death", "description": "HF = Heart Failure, CV = Cardiovascular\n\nNumber of days lost due to heart failure hospitalisations or cardiovascular death corresponds to the total number of days in hospital for heart failure from randomisation to last known date. Days lost due to cardiovascular death are added to the number of days lost due to heart failure hospitalisation.", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.\n\nThe management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "at 52 weeks after randomisation", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"title": "Full Analysis Set (FAS)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8", "spread": "9.06"}, {"groupId": "OG001", "value": "6.2", "spread": "14.48"}]}]}, {"title": "COVID-19 sensitivity analyses", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.5", "spread": "8.18"}, {"groupId": "OG001", "value": "6.1", "spread": "14.42"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Full Analysis Set (FAS)", "nonInferiorityType": "OTHER", "pValue": "0.035", "statisticalMethod": "Negative binomial model", "statisticalComment": "Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.", "paramType": "Annualised event rate ratio (RR)", "paramValue": "0.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.47", "ciUpperLimit": "0.97"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Covid-19 Sensitivity Analysis", "nonInferiorityType": "OTHER", "pValue": "0.009", "statisticalMethod": "Negative binomial model", "statisticalComment": "Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country", "paramType": "Annualised event rate ratio (RR)", "paramValue": "0.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.42", "ciUpperLimit": "0.88"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "HF Hospitalisations", "description": "HF = Heart Failure\n\nNumber of participants with at least one HF Hospitalisation up to 52 weeks after randomisation", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "up to 52 weeks after randomisation", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "178"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Full Analysis Set (FAS)", "nonInferiorityType": "OTHER", "pValue": "0.006", "statisticalMethod": "Regression, Cox", "statisticalComment": "Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline.", "paramType": "Hazard Ratio (HR)", "paramValue": "0.73", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.59", "ciUpperLimit": "0.92"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "CV Hospitalisations", "description": "CV = Cardiovascular\n\nNumber of participants with at least one CV Hospitalisation up to 52 weeks after randomisation", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "up to 52 weeks after randomisation", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "181"}, {"groupId": "OG001", "value": "220"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Full Analysis Set (FAS)", "nonInferiorityType": "OTHER", "pValue": "0.009", "statisticalMethod": "Regression, Cox", "statisticalComment": "Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline.", "paramType": "Hazard Ratio (HR)", "paramValue": "0.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.63", "ciUpperLimit": "0.94"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "All-cause Mortality", "description": "Number of participants who died up to 52 weeks after randomisation", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "up to 52 weeks after randomisation", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates"}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "96"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Full Analysis Set (FAS)", "nonInferiorityType": "OTHER", "pValue": "0.944", "statisticalMethod": "Regression, Cox", "statisticalComment": "Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline", "paramType": "Hazard Ratio (HR)", "paramValue": "0.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.75", "ciUpperLimit": "1.31"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in NYHA Functional Class", "description": "NYHA = New York Heart Association\n\nNYHA functional class was assessed as Class I, II, III, IV or V:\n\nClass I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.\n\nClass II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.\n\nClass III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest.\n\nClass IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. If a participant was hospitalised at any point during any post-baseline visit and did not have any NYHA assessment for this visit, then Class IV was to be imputed for the visit.\n\nClass V - Imputed for participants who died.\n\nLower response categories are better for score NYHA.", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "at 6, 12, 24 and 52 weeks after randomisation", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates"}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "557"}, {"groupId": "OG001", "value": "547"}]}], "categories": [{"title": "Class I", "measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "8"}]}, {"title": "Class II", "measurements": [{"groupId": "OG000", "value": "255"}, {"groupId": "OG001", "value": "240"}]}, {"title": "Class III", "measurements": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "277"}]}, {"title": "Class IV", "measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "22"}]}, {"title": "Class V", "measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "516"}, {"groupId": "OG001", "value": "514"}]}], "categories": [{"title": "Class I", "measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "38"}]}, {"title": "Class II", "measurements": [{"groupId": "OG000", "value": "296"}, {"groupId": "OG001", "value": "271"}]}, {"title": "Class III", "measurements": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "151"}]}, {"title": "Class IV", "measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "31"}]}, {"title": "Class V", "measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "23"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "492"}, {"groupId": "OG001", "value": "488"}]}], "categories": [{"title": "Class I", "measurements": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "40"}]}, {"title": "Class II", "measurements": [{"groupId": "OG000", "value": "296"}, {"groupId": "OG001", "value": "267"}]}, {"title": "Class III", "measurements": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "131"}]}, {"title": "Class IV", "measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "18"}]}, {"title": "Class V", "measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "32"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "492"}, {"groupId": "OG001", "value": "495"}]}], "categories": [{"title": "Class I", "measurements": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "47"}]}, {"title": "Class II", "measurements": [{"groupId": "OG000", "value": "288"}, {"groupId": "OG001", "value": "265"}]}, {"title": "Class III", "measurements": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "100"}]}, {"title": "Class IV", "measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "20"}]}, {"title": "Class V", "measurements": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "63"}]}]}, {"title": "Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "449"}, {"groupId": "OG001", "value": "463"}]}], "categories": [{"title": "Class I", "measurements": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "53"}]}, {"title": "Class II", "measurements": [{"groupId": "OG000", "value": "234"}, {"groupId": "OG001", "value": "223"}]}, {"title": "Class III", "measurements": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "75"}]}, {"title": "Class IV", "measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "17"}]}, {"title": "Class V", "measurements": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "95"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Full Analysis Set (FAS)", "nonInferiorityType": "OTHER", "pValue": "0.196", "statisticalMethod": "Generalised Estimating Equations (GEE)", "statisticalComment": "The following variables are included in the GEE model: treatment, visit, baseline NYHA class, sex, age, HF aetiology, HF duration, and country", "paramType": "Odds Ratio (OR)", "paramValue": "1.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.93", "ciUpperLimit": "1.39"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in the EQ-5D-5L Questionnaire Indexed Value", "description": "EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels\n\nThe EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration.\n\nThe descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Change from baseline in EQ-5D-5L", "timeFrame": "at 6, 24 and 52 weeks after randomisation", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"title": "Week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "476"}, {"groupId": "OG001", "value": "465"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "0.01"}, {"groupId": "OG001", "value": "0.03", "spread": "0.01"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "422"}, {"groupId": "OG001", "value": "410"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.01"}, {"groupId": "OG001", "value": "0.05", "spread": "0.01"}]}]}, {"title": "Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "365"}, {"groupId": "OG001", "value": "363"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.01"}, {"groupId": "OG001", "value": "0.06", "spread": "0.01"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Week 6", "nonInferiorityType": "OTHER", "pValue": "0.208", "statisticalMethod": "Mixed-effect model of repeated measures", "statisticalComment": "MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\\*Visit + Baseline covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 24", "nonInferiorityType": "OTHER", "pValue": "0.408", "statisticalMethod": "Mixed-effect model of repeated measures", "statisticalComment": "MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\\*Visit + Baseline covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 52", "nonInferiorityType": "OTHER", "pValue": "0.999", "statisticalMethod": "Mixed-effect model of repeated measures", "statisticalComment": "MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\\*Visit + Baseline covariates."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "KCCQ-12 Repeated-Measures Model for Analysis of Treatment Difference", "description": "KCCQ = Kansas City Cardiomyopathy Questionnaire\n\nThe KCCQ 12 is a health-related quality of life questionnaire for Heart Failure. It is a 12 item questionnaire that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge and Quality of life. Scores are generated for each domain and scaled from 0 to 100, with 0 denoting the lowest reportable health status and 100 the highest reportable health status.", "populationDescription": "Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "KCCQ-12 score", "timeFrame": "up to 52 weeks after randomisation", "groups": [{"id": "OG000", "title": "FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates."}, {"id": "OG001", "title": "Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "558"}, {"groupId": "OG001", "value": "550"}]}], "classes": [{"title": "Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "490"}, {"groupId": "OG001", "value": "484"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.53", "spread": "1.16"}, {"groupId": "OG001", "value": "17.24", "spread": "1.19"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "476"}, {"groupId": "OG001", "value": "480"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "21.26", "spread": "1.18"}, {"groupId": "OG001", "value": "18.36", "spread": "1.21"}]}]}, {"title": "Week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "475"}, {"groupId": "OG001", "value": "461"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "23.49", "spread": "1.20"}, {"groupId": "OG001", "value": "19.88", "spread": "1.23"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "439"}, {"groupId": "OG001", "value": "451"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.57", "spread": "1.24"}, {"groupId": "OG001", "value": "21.88", "spread": "1.26"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "422"}, {"groupId": "OG001", "value": "413"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "26.30", "spread": "1.26"}, {"groupId": "OG001", "value": "23.32", "spread": "1.27"}]}]}, {"title": "Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "386"}, {"groupId": "OG001", "value": "379"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.78", "spread": "1.28"}, {"groupId": "OG001", "value": "23.70", "spread": "1.30"}]}]}, {"title": "Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "368"}, {"groupId": "OG001", "value": "370"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.75", "spread": "1.33"}, {"groupId": "OG001", "value": "24.31", "spread": "1.34"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Week 2", "nonInferiorityType": "OTHER", "pValue": "0.227", "statisticalMethod": "Mixed-effect model of repeated measures", "statisticalComment": "MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\\*Visit + Baseline covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 4", "nonInferiorityType": "OTHER", "pValue": "0.018", "statisticalMethod": "Mixed-effect model of repeated measures", "statisticalComment": "MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\\*Visit + Baseline covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 6", "nonInferiorityType": "OTHER", "pValue": "0.005", "statisticalMethod": "Mixed-effect model of repeated measures", "statisticalComment": "MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\\*Visit + Baseline covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 12", "nonInferiorityType": "OTHER", "pValue": "0.006", "statisticalMethod": "Mixed-effect model of repeated measures", "statisticalComment": "MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\\*Visit + Baseline covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 24", "nonInferiorityType": "OTHER", "pValue": "0.028", "statisticalMethod": "Mixed-effect model of repeated measures", "statisticalComment": "MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\\*Visit + Baseline covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 36", "nonInferiorityType": "OTHER", "pValue": "0.136", "statisticalMethod": "Mixed-effect model of repeated measures", "statisticalComment": "MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\\*Visit + Baseline covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 52", "nonInferiorityType": "OTHER", "pValue": "0.329", "statisticalMethod": "Mixed-effect model of repeated measures", "statisticalComment": "MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\\*Visit + Baseline covariates."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "During treatment period up to 52 weeks after randomization", "eventGroups": [{"id": "EG000", "title": "Group 1 - FCM (Ferric Carboxymaltose)", "description": "Ferric carboxymaltose (FCM), administered by bolus IV injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the subject's body weight and Hb level.\n\nFrom a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the subject's Hb levels measured prior to planned dosing dates.", "deathsNumAffected": 99, "deathsNumAtRisk": 559, "seriousNumAffected": 250, "seriousNumAtRisk": 559, "otherNumAffected": 51, "otherNumAtRisk": 559}, {"id": "EG001", "title": "Group 2 - Placebo (Normal Saline (NaCl 0.9%))", "description": "Normal saline (NaCl 0.9%), administered by bolus IV injection at a volume corresponding to the FCM dose determined by the subject's body weight and Hb level (i.e., 10 ml or 20 ml per administration).", "deathsNumAffected": 96, "deathsNumAtRisk": 551, "seriousNumAffected": 282, "seriousNumAtRisk": 551, "otherNumAffected": 45, "otherNumAtRisk": 551}], "seriousEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 163, "numAffected": 116, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 215, "numAffected": 127, "numAtRisk": 551}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 21, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 23, "numAffected": 17, "numAtRisk": 551}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 32, "numAffected": 20, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 35, "numAffected": 23, "numAtRisk": 551}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 551}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 12, "numAffected": 11, "numAtRisk": 551}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 551}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Ventricular arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 551}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 4, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 551}]}, {"term": "Bradyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Ventricular fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Acute left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Atrioventricular block complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Cardiopulmonary failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Congestive cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 551}]}, {"term": "Mitral valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 551}]}, {"term": "Sinus node dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Tachyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Aortic valve disease mixed", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Atrioventricular block second degree", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Cardiac amyloidosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Cardiorenal syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Left ventricular dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Nodal arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Pericarditis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Sinus bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Ventricular dyssynchrony", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 16, "numAffected": 15, "numAtRisk": 551}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 9, "numAffected": 9, "numAtRisk": 551}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 551}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Dengue fever", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Osteomyelitis chronic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Skin infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Staphylococcal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Suspected COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Abdominal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Arthritis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Carbuncle", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Clostridium difficile colitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Enterococcal bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Infected skin ulcer", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Intervertebral discitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Pneumonia klebsiella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Shewanella algae bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Tracheobronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 551}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 551}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 551}]}, {"term": "Multiple organ dysfunction syndrome", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 551}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Generalised oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 551}]}, {"term": "Cerebrovascular disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Altered state of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Carotid artery stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Cerebral ischaemia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Cerebrovascular insufficiency", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Haemorrhagic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 551}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Coma", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Haemorrhage intracranial", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Thrombotic cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 551}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 551}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Acute pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Dyspnoea at rest", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Pulmonary congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 551}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Apnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Choking", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Dyspnoea exertional", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Hydrothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Orthopnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 551}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 551}]}, {"term": "Chronic kidney disease", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "End stage renal disease", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Diabetic nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Urinary tract inflammation", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Post procedural haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Toxicity to various agents", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Alcohol poisoning", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Facial bones fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Multiple fractures", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Pharyngeal injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Subdural haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Vascular pseudoaneurysm", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Postoperative thoracic procedure complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Skin abrasion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Traumatic haemothorax", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Peripheral vascular disorder", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Aortic dissection", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Circulatory collapse", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Diabetic vascular disorder", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Peripheral artery occlusion", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Peripheral artery thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Peripheral ischaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Shock", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Varicose ulceration", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Ileus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Large intestinal ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Presbyoesophagus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 551}]}, {"term": "Ascites", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Enterocolitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Gastric disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Gastric perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Gastric ulcer haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Gastrointestinal perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Intestinal infarction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Intestinal ischaemia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Melaena", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 3, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Fluid overload", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Hyperglycaemic hyperosmolar nonketotic syndrome", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Cachexia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Electrolyte imbalance", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Rectal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Hepatic neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Malignant neoplasm progression", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Metastases to central nervous system", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Metastases to liver", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Bronchial carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Pancreatic carcinoma metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Plasma cell myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Fracture nonunion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Joint effusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Periarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Flank pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Gouty arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Sarcopenia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Spinal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 551}]}, {"term": "Lymphadenopathy mediastinal", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Microcytic anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Pancytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Hepatic failure", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Jaundice cholestatic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Bile duct stone", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Cholangitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Hepatic steatosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Jaundice", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 551}]}, {"term": "Diabetic foot", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Hyperthyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Corneal decompensation", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Ulcerative keratitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Device malfunction", "organSystem": "Product Issues", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 551}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Delirium", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Disorientation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Heart transplant rejection", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Heart rate abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Blood lactate dehydrogenase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Ejection fraction decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "International normalised ratio decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Abortion incomplete", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 551}]}, {"term": "Deafness unilateral", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Hypoacusis", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Prostatitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 551}]}], "otherEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 57, "numAffected": 51, "numAtRisk": 559}, {"groupId": "EG001", "numEvents": 49, "numAffected": 45, "numAtRisk": 551}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "FER-CARS-06 Clinical Study Team", "organization": "Vifor (International) AG.", "email": "FER-CARS-06.study@viforpharma.com", "phone": "+41 588 518 000"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-04-01", "uploadDate": "2021-04-22T13:09", "filename": "Prot_000.pdf", "size": 1315589}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-08-26", "uploadDate": "2021-04-22T13:10", "filename": "SAP_001.pdf", "size": 8420552}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000018798", "term": "Anemia, Iron-Deficiency"}, {"id": "D000090463", "term": "Iron Deficiencies"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000019189", "term": "Iron Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000000747", "term": "Anemia, Hypochromic"}, {"id": "D000000740", "term": "Anemia"}, {"id": "D000006402", "term": "Hematologic Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M20857", "name": "Anemia, Iron-Deficiency", "asFound": "Iron Deficiency", "relevance": "HIGH"}, {"id": "M2781", "name": "Iron Deficiencies", "asFound": "Iron Deficiency", "relevance": "HIGH"}, {"id": "M4070", "name": "Anemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M21177", "name": "Iron Metabolism Disorders", "relevance": "LOW"}, {"id": "M4077", "name": "Anemia, Hypochromic", "relevance": "LOW"}, {"id": "M9490", "name": "Hematologic Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC15", "name": "Blood and Lymph Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M207501", "name": "Chrysarobin", "relevance": "LOW"}, {"id": "M10533", "name": "Iron", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}]}}, "hasResults": true}